---
title: "The controlling shareholder of Black Cat Carbon has cumulatively increased its holdings in the company by 2.627 million shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230791764.md"
description: "According to the announcement from Black Cat Carbon, as of the disclosure date of the announcement, the implementation period of this share buyback plan has passed halfway. The controlling shareholder, Black Cat Group, has cumulatively increased its holdings by 2.627 million shares, accounting for 0.36% of the company's current total share capital. This share buyback plan has not yet been fully implemented, and Black Cat Group will continue to increase its holdings in accordance with the relevant buyback plan within the implementation period"
datetime: "2025-03-06T08:40:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230791764.md)
  - [en](https://longbridge.com/en/news/230791764.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230791764.md)
generator: "portal-rs"
---

# The controlling shareholder of Black Cat Carbon has cumulatively increased its holdings in the company by 2.627 million shares

According to the announcement from Zhitong Finance APP, Black Cat Carbon (002068.SZ) has announced that as of the date of the announcement, the implementation period of this share buyback plan has passed halfway. The controlling shareholder, Black Cat Group, has cumulatively increased its holdings by 2.627 million shares, accounting for 0.36% of the company's current total share capital. The share buyback plan has not yet been fully implemented, and Black Cat Group will continue to increase its holdings in accordance with the relevant buyback plan within the implementation period

### Related Stocks

- [002068.CN](https://longbridge.com/en/quote/002068.CN.md)

## Related News & Research

- [Most vertically-integrated company ever, SpaceX share price will triple by end of decade: Investor](https://longbridge.com/en/news/296298699.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)
- [DIMRI: H1 2026 net profit rose to ₪495.6M on revenue of ₪780.5M, with robust liquidity and equity](https://longbridge.com/en/news/296448412.md)
- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**